Related Experiment Video
Updated: Sep 9, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in
Guillaume Baille1, Nathalie Patte-Karsenti1, Quentin Salardaine1
1Department of Neurology, Fondation Rothschild Hospital, Paris Cité University, Paris, France.
Background:
Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is a novel non-surgical alternative to levodopa/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real-world switch data remain limited.
Objectives:
To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI.
Methods:
We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non-motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6).
Results:
Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ-8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions.
Conclusion:
Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.
More Related Videos
06:40Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
Published on: April 23, 2020
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Two-Compartment Open Model: IV Bolus Administration
The disparity between drug input and the sum of drug transfer rates between...
Continuous Renal Replacement Therapy
Parkinson's Disease: Overview